AT<sub>1</sub>Receptor Blockade Improves Myocardial Functional Performance in Obesity

Oliveira-Junior, Silvio Assis de; Muzili, Nayara de Araújo; Carvalho, Marianna Rabelo de; Ota, Gabriel Elias; Morais, Camila Souza de; Vieira, Larissa Fregapani da Costa; Ortiz, Mateus Oliveira; Campos, Dijon H. S.; Cezar, Marcelo Diacardia Mariano; Okoshi, Marina Politi; Okoshi, Katashi; Cicogna, Antonio C.; Martinez, Paula Felippe

doi:10.36660/abc.20190131

person Silvio Assis de Oliveira-Junior

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

0000-0002-8895-9456

person Nayara de Araújo Muzili

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

person Marianna Rabelo de Carvalho

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

0000-0001-9789-2487

person Gabriel Elias Ota

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

person Camila Souza de Morais

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

person Larissa Fregapani da Costa Vieira

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

person Mateus Oliveira Ortiz

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

person Dijon H. S. Campos

schoolFaculdade de Medicina de Botucatu – UNESP, Botucatu, SP - Brazil

0000-0002-4933-0604

person Marcelo Diacardia Mariano Cezar

schoolFaculdade de Ciências Sociais e Agrárias de Itapeva (FAIT), Itapeva, SP - BrazilschoolUniversidade Estadual de São Paulo (UNESP), Departamento de Medicina Interna, Botucatu, SP - Brazil

0000-0003-4829-9606

person Marina Politi Okoshi

schoolUniversidade Estadual de São Paulo (UNESP), Departamento de Medicina Interna, Botucatu, SP - Brazil

0000-0001-7728-4505

person Katashi Okoshi

schoolUniversidade Estadual Paulista Júlio de Mesquita Filho - Faculdade de Medicina - Campus de Botucatu, Botucatu, SP - Brazil

person Antonio C. Cicogna

schoolFaculdade de Medicina de Botucatu – UNESP, Botucatu, SP - Brazil

0000-0002-4402-6523

person Paula Felippe Martinez

schoolUniversidade Federal de Mato Grosso do Sul, Campo Grande, MS – Brazil

0000-0001-9477-3386

Mailing Address: Silvio Assis de Oliveira-Junior • Federal University of Mato Grosso do Sul - Laboratory of Striated Muscle Study (LEME) - Av. Costa e Silva, s/n Cidade Universitária Campo Grande, MS – Brazil E-mail: oliveirajr.ufms@gmail.com, silvio.oliveira-jr@ufms.br

Author contributions

Conception and design of the research: Oliveira-Junior SA, Okoshi MP, Martinez PF; Acquisition of data: Muzili NA, Carvalho MR, Ota GE, Morais CS, Vieira LFC, Ortiz MO, Campos DHS, Cezar MDM, Okoshi K; Analysis and interpretation of the data: Oliveira-Junior SA, Campos DHS, Cezar MDM, Okoshi MP, Okoshi K, Cicogna AC, Martinez PF; Statistical analysis and writing of the manuscript: Oliveira-Junior SA; Obtaining financing: Oliveira-Junior SA, Martinez PF; Critical revision of the manuscript for intellectual content: Okoshi MP, Okoshi K, Cicogna AC, Martinez PF.

Potential Conflict of Interest

No potential conflict of interest relevant to this article was reported.

Figures (4)
Tables (2)

Thumbnail

Figure 1 – Functional papillary muscle assessment at baseline with extracellular [Ca²⁺] equal to 2.5 mM; results in mean±SD; (A) DT: maximum developed tension; (B) +dT/dt: maximum DT variation speed; (C) –dT/dt: maximum DT decrease; CO: Control group; OB: Obese group; CL: Control Losartan group; OL: Obese Losartan group. * p<0.05 compared to CO; Two-Way ANOVA and Tukey Test.

Thumbnail

Figure 2 – Functional papillary muscle assessment according to extracellular calcium concentration (1.0-2.5 mM). Results expressed regarding the baseline with extracellular [Ca²⁺] equal to 0.5 mM value (mean±SD); (A) DT: maximum developed tension; (B) +dT/dt: maximum positive DT change; (C) -dT/dt, maximum DT decrease. CO: Control group; CL: Control Losartan group; OB: Obese group; OL: Obese Losartan group. Group’s effect: † p<0.05 compared to OB; ‡ p<0.05 compared to CL. Calcium’s Effect: §, p<0.05 compared to 1.0 mM; ¶, p<0.05 compared to 1.5 mM; Two-Way RM ANOVA and Bonferroni Test.

Thumbnail

Figure 3 – Isolated papillary muscle assessement, according to post-pause potentiation (PPP) time. Results are expressed regarding the baseline with extracellular [Ca²⁺] equal to 0.5 mM value (mean±SD); (A) DT: maximum developed tension; (B) +dT/dt: maximum positive DT change; (C) –dT/dt: maximum DT decrease; CO: Control group; CL: Control Losartan group; OB: Obese group; OL: Obese Losartan group. PPP’s effect: §, p<0.05 compared to 30s; Group’s effect: * p<0.05 vs CO; † p<0.05 compared to OB; ‡ p<0.05 compared to CL. Two-Way RM ANOVA and Bonferroni Test.

Thumbnail

Figure 4 – Functional assessment of the isolated papillary muscle, according to Isoproterenol concentration. Results expressed regarding the baseline with extracellular [Ca²⁺] equal to 1.0 mM value (mean±SD); (A) DT: maximum developed tension; (B) +dT/dt: maximum positive DT change; (C) -dT/dt: maximum DT decrease; CO: Control group; OB: Obese group; CL: Control Losartan group; OL: Obese group under Losartan. Group’s effect: * p<0.05 compared to C; ‡ p<0.05 compared to CL. Isoproterenol’s Effect: §, p<0.05 compared to Baseline; ¶, p<0.05 vs 0.1 mM; Two-Way RM ANOVA and Bonferroni Test.

Thumbnail

Table 1 – Mean and standard deviation of nutritional variables, murinometry and cardiac morphology according with group

Thumbnail

Table 2 – Mean and standard deviation of systolic blood pressure, measures of structure and functional performance of the heart analyzed by echocardiogram and left ventricular tissue Doppler, according to group and time of assessment

Variable		Group

		CO	OB	CL	OL
Nutritional Profile	Body weight (g)	451 ± 58	507 ± 64 *	456 ± 49	517 ± 50^‡
	Caloric intake (Kcal)	81.9 ± 8.2	80.7 ± 7.5	80.3 ± 9.2	78.7 ± 7.9
	Total intake of unsaturated lipids (g)	122 ± 12	235 ± 22 *	120 ± 14	230 ± 23^‡
	Total intake of saturated lipids (g)	196 ± 20	433 ± 40 *	193 ± 22	422 ± 43^‡
	Feed efficiency (%)	26.82 ± 2.11	32.22 ± 4.38 *	28.43 ± 0.94	35.12 ± 4.78^‡
	Adiposity (%)	3.48 ± 0.73	5.19 ± 1.47 *	3.61 ± 1.27	5.50 ± 1.48^‡
Cardiac Morphology	Atria (g)	0.096 ± 0.015	0.113 ± 0.015 *	0.092 ± 0.009	0.100 ± 0.022^†
	Atria/ Tibia (mg/mm)	2.22 ± 0.33	2.59 ± 0.35 *	2.15 ± 0.21	2.29 ± 0.46^†
	RVW (g)	0.231 ± 0.029	0.241 ± 0.030	0.230 ± 0.039	0.245 ± 0.040
	RVW/Tibia (mg/mm)	5.36 ± 0.68	5.50 ± 0.70	5.34 ± 0.79	5.64 ± 0.86
	LVW (g)	0.844 ± 0.083	0.950 ± 0.099	0.800 ± 0.082 *	0.799 ± 0.087^†
	LVW/Tibia (mg/mm)	19.6 ± 1.7	21.7 ± 2.4 *	18.7 ± 1.5	18.4 ± 1.7^†

Variable	Moment	Group

		CO	OB	CL	OL
SBP (mmHg)	16th Wks	119.4 ± 9.2	133.3 ± 12.3 *	119.5 ± 9.4	132.0 ± 9.6^‡
SBP (mmHg)	20th Wks	129.6 ± 9.3	139.3 ± 12.6	103.0 ± 13.2 *^§	107.7 ± 7.4^{† §}
HR (bpm)	16th Wks	277 ± 41	272 ± 27	276 ± 48	273 ± 44
HR (bpm)	20th Wks	285 ± 32	266 ± 39	265 ± 39	277 ± 39
LA (mm)	16th Wks	5.47 ± 0.79	5.80 ± 0.60	5.87 ± 0.74	5.81 ± 0.89
LA (mm)	20th Wks	5.69 ± 0.56	5.95 ± 0.55	5.70 ± 0.60	5.77 ± 0.67
LA/AO	16th Wks	1.37 ± 0.18	1.45 ± 0.14	1.48 ± 0.14	1.42 ± 0.18
LA/AO	20th Wks	1.42 ± 0.16	1.44 ± 0.10	1.40 ± 0.11	1.42 ± 0.12
LVDT (mm)	16th Wks	1.317 ± 0.072	1.374 ± 0.044	1.313 ± 0.071	1.361 ± 0.058
LVDT (mm)	20th Wks	1.272 ± 0.067^§	1.305 ± 0.043^§	1.262 ± 0.085^§	1.271 ± 0.061^§
LVDD (mm)	16th Wks	7.95 ± 0.64	7.91 ± 0.37	7.80 ± 0.57	7.82 ± 0.44
LVDD (mm)	20th Wks	8.11 ± 0.41	8.15 ± 0.26	8.06 ± 0.54	8.08 ± 0.52
LVDD/ Tibia (mm/mm)	16th Wks	0.184 ± 0.015	0.180 ± 0.008	0.182 ± 0.012	0.180 ± 0.007
LVDD/ Tibia (mm/mm)	20th Wks	0.188 ± 0.010	0.186 ± 0.007	0.188 ± 0.011	0.187 ± 0.012
LVSD (mm)	16th Wks	3.65 ± 0.68	3.56 ± 0.39	3.54 ± 0.65	3.69 ± 0.56
LVSD (mm)	20th Wks	3.66 ± 0.42	3.55 ± 0.50	3.86 ± 0.67	3.75 ± 0.62
PWSV (mm/s)	16th Wks	40.44 ± 4.70	43.63 ± 2.95	42.31 ± 5.11	39.29 ± 3.96
PWSV (mm/s)	20th Wks	42.92 ± 4.45	48.72 ± 4.81 *^§	42.82 ± 3.60	47.96 ± 4.03^{‡ §}
EF	16th Wks	0.900 ± 0.039	0.907 ± 0.023	0.903 ± 0.037	0.892 ± 0.037
EF	20th Wks	0.907 ± 0.022	0.914 ± 0.033	0.887 ± 0.039	0.898 ± 0.037
ES (%)	16th Wks	54.32 ± 6.38	55.00 ± 3.72	54.83 ± 6.28	52.92 ± 5.41
ES (%)	20th Wks	54.94 ± 3.58	56.49 ± 5.67	52.34 ± 5.73	53.83 ± 5.45
E/A	16th Wks	1.65 ± 0.35	1.49 ± 0.25	1.52 ± 0.25	1.43 ± 0.23
E/A	20th Wks	1.60 ± 0.33	1.50 ± 0.23	1.74 ± 0.27	1.39 ± 0.26^‡
EDT (ms)	16th Wks	50.09 ± 6.85	49.50 ± 4.56	47.64 ± 8.69	51.10 ± 6.19
EDT (ms)	20th Wks	47.64 ± 7.47	50.58 ± 6.59	50.17 ± 5.84	54.40 ± 5.77
IVRT	16th Wks	58.88 ± 6.98	58.12 ± 4.22	55.38 ± 7.72	54.66 ± 5.26
IVRT	20th Wks	53.60 ± 4.22	52.47 ± 4.87	53.49 ± 7.17	52.72 ± 3.78
S’(cm/s)	16th Wks	3.57 ± 0.31	3.79 ± 0.28	3.72 ± 0.24	3.79 ± 0.45
S’(cm/s)	20th Wks	4.00 ± 0.24^§	4.05 ± 0.47	3.91 ± 0.29	4.19 ± 0.27^§
E’ (cm/s)	16th Wks	4.62 ± 0.53	4.23 ± 0.40	4.25 ± 0.39	4.04 ± 0.53
E’ (cm/s)	20th Wks	4.85 ± 0.57	4.80 ± 0.32^§	4.83 ± 0.38^§	4.92 ± 0.52^§
A’ (cm/s)	16th Wks	3.75 ± 0.86	3.85 ± 0.59	3.78 ± 0.83	3.49 ± 0.50
A’ (cm/s)	20th Wks	4.37 ± 0.87	3.78 ± 1.08	3.61 ± 0.75 *	4.31 ± 0.81^§
E/E’	16th Wks	16.80 ± 3.62	18.76 ± 3.13	18.12 ± 2.27	18.86 ± 2.61
E/E’	20th Wks	17.89 ± 2.59	18.79 ± 2.35	17.27 ± 1.52	17.22 ± 2.51

[TFN1001] RVW: right ventricular weight; LVW: left ventricular weight; CO: Control group; OB: Obese group; CL: Control Losartan group; OL: Obese Losartan group Group’s effects: * p <0.05 compared to CO; † p <0.05 compared to OB; ‡ p <0.05 compared to CL; Two-Way ANOVA and Tukey test.

AT₁Receptor Blockade Improves Myocardial Functional Performance in Obesity

Abstract

AT1Receptor Blockade Improves Myocardial Functional Performance in Obesity

Abstract

AT₁Receptor Blockade Improves Myocardial Functional Performance in Obesity